临床肿瘤学中的组织微阵列
Tissue microarrays in clinical oncology.
作者信息
Voduc David, Kenney Challayne, Nielsen Torsten O
机构信息
Department of Radiation Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada.
出版信息
Semin Radiat Oncol. 2008 Apr;18(2):89-97. doi: 10.1016/j.semradonc.2007.10.006.
Abstract
Tissue microarray (TMA) is a recently implemented, high-throughput technology for the analysis of molecular markers in oncology. This research tool permits the rapid assessment of a biomarker in thousands of tumor samples, using commonly available laboratory assays such as immunohistochemistry and in situ hybridization. Although introduced less than a decade ago, TMA has proven to be invaluable in the study of tumor biology, the development of diagnostic tests, and the investigation of oncologic biomarkers. This review describes the impact of TMA-based research in clinical oncology and its potential future applications. Technical aspects of TMA construction and the advantages and disadvantages inherent to this technology are also discussed.
摘要
组织微阵列（TMA）是一种最近应用的高通量技术，用于肿瘤学中分子标志物的分析。这种研究工具能够通过免疫组织化学和原位杂交等常用实验室检测方法，对数千个肿瘤样本中的生物标志物进行快速评估。尽管TMA问世还不到十年，但已被证明在肿瘤生物学研究、诊断测试开发以及肿瘤生物标志物研究中具有极高价值。本文综述了基于TMA的研究在临床肿瘤学中的影响及其未来潜在应用。同时也讨论了TMA构建的技术方面以及该技术固有的优缺点。
相似文献
1
Tissue microarrays in clinical oncology.临床肿瘤学中的组织微阵列
Semin Radiat Oncol. 2008 Apr;18(2):89-97. doi: 10.1016/j.semradonc.2007.10.006.
2
[Tissue microarrays a powerful tool in transfer and quality control in oncology].[组织微阵列：肿瘤学中转移和质量控制的强大工具]
Bull Cancer. 2003 Jan;90(1):31-8.
3
Experiences from tissue microarray in soft tissue sarcomas.软组织肉瘤组织芯片的经验
Acta Orthop Scand Suppl. 2004 Apr;75(311):29-34. doi: 10.1080/00016470410001708300.
4
Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies.组织微阵列（TMA）技术：用于高通量原位研究的小型化病理档案
J Pathol. 2001 Sep;195(1):72-9. doi: 10.1002/path.893.
5
Tissue microarrays for high-throughput molecular pathology.用于高通量分子病理学的组织微阵列
Ann Saudi Med. 2004 May-Jun;24(3):169-74. doi: 10.5144/0256-4947.2004.169.
6
Tissue microarray technology: principles, pitfalls and perspectives--lessons learned from hematological malignancies.组织微阵列技术：原理、陷阱与展望——血液系统恶性肿瘤的经验教训
Exp Gerontol. 2005 Aug-Sep;40(8-9):737-44. doi: 10.1016/j.exger.2005.06.011.
7
Tissue microarray (TMA) applications: implications for molecular medicine.组织微阵列（TMA）的应用：对分子医学的影响。
Expert Rev Mol Med. 2003 Oct 21;5(26):1-12. doi: 10.1017/S1462399403006781.
8
[Application of tissue microarrays for the diagnosis, prognosis and therapeutic decision making in renal cell carcinoma].组织芯片在肾细胞癌诊断、预后及治疗决策中的应用
Urologe A. 2006 Mar;45(3):323-4, 326-7. doi: 10.1007/s00120-006-1005-y.
9
A review of the applications of tissue microarray technology in understanding the molecular features of endometrial carcinoma.组织芯片技术在子宫内膜癌分子特征研究中的应用综述
Anal Quant Cytol Histol. 2009 Aug;31(4):217-26.
10
Protocols for Tissue Microarrays in Prostate Cancer Studies.前列腺癌研究中组织微阵列的方案
Methods Mol Biol. 2018;1786:103-116. doi: 10.1007/978-1-4939-7845-8_6.
引用本文的文献
1
Association of Enterotoxigenic with Immune Modulation in Colorectal Cancer Liver Metastasis.产肠毒素菌与结直肠癌肝转移中免疫调节的关联
Cancers (Basel). 2025 Aug 22;17(17):2733. doi: 10.3390/cancers17172733.
2
Multiplex Immunofluorescence Reveals Therapeutic Targets EGFR, EpCAM, Tissue Factor, and TROP2 in Triple-Negative Breast Cancer.多重免疫荧光揭示三阴性乳腺癌中的治疗靶点表皮生长因子受体（EGFR）、上皮细胞黏附分子（EpCAM）、组织因子和人滋养层细胞表面抗原2（TROP2）
Int J Mol Sci. 2025 Aug 1;26(15):7430. doi: 10.3390/ijms26157430.
3
MIMIC: a flexible pipeline to register and summarize IMC-MSI experiments.MIMIC：一个用于注册和总结IMC-MSI实验的灵活流程。
bioRxiv. 2025 Jul 23:2025.07.08.663623. doi: 10.1101/2025.07.08.663623.
4
Serous Ovarian Carcinoma: Detailed Analysis of Clinico-Pathological Characteristics as Prognostic Factors.浆液性卵巢癌：作为预后因素的临床病理特征详细分析
Cancers (Basel). 2024 Oct 25;16(21):3611. doi: 10.3390/cancers16213611.
5
Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases.免疫功能障碍通过数字空间分析免疫肿瘤标志物在肾细胞癌进展阶段和脑转移中的揭示。
J Immunother Cancer. 2023 Aug;11(8). doi: 10.1136/jitc-2023-007240.
6
The relationship of lifetime history of depression on the ovarian tumor immune microenvironment.抑郁症终生史与卵巢肿瘤免疫微环境的关系。
Brain Behav Immun. 2023 Nov;114:52-60. doi: 10.1016/j.bbi.2023.08.006. Epub 2023 Aug 7.
7
Combination of Tissue Microarray Profiling and Multiplexed IHC Approaches to Investigate Transport Mechanism of Nucleoside Analog Drug Resistance.联合组织微阵列分析和多重免疫组化方法研究核苷类似物耐药的转运机制。
Methods Mol Biol. 2023;2660:95-121. doi: 10.1007/978-1-0716-3163-8_8.
8
Prognostic value of epigenetic markers for canine mast cell cancer.表观遗传学标志物对犬肥大细胞瘤预后的价值。
PLoS One. 2023 Mar 30;18(3):e0283616. doi: 10.1371/journal.pone.0283616. eCollection 2023.
9
Automated Lung Cancer Segmentation in Tissue Micro Array Analysis Histopathological Images Using a Prototype of Computer-Assisted Diagnosis.在组织微阵列分析组织病理学图像中使用计算机辅助诊断原型进行肺癌自动分割
J Pers Med. 2023 Feb 23;13(3):388. doi: 10.3390/jpm13030388.
10
Advancements in Oncoproteomics Technologies: Treading toward Translation into Clinical Practice.肿瘤蛋白质组学技术的进展：迈向临床实践转化
Proteomes. 2023 Jan 10;11(1):2. doi: 10.3390/proteomes11010002.
本文引用的文献
1
Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications--a study from the Lunenburg Lymphoma Biomarker Consortium.弥漫性大B细胞淋巴瘤中的免疫组织化学预后标志物：组织芯片作为广泛临床应用前提条件的验证——来自吕嫩堡淋巴瘤生物标志物联盟的一项研究
J Clin Oncol. 2007 Mar 1;25(7):805-12. doi: 10.1200/JCO.2006.09.4490.
2
Immunohistochemical staining for p63 is useful in the diagnosis of anal squamous cell carcinomas.p63免疫组织化学染色有助于肛管鳞状细胞癌的诊断。
Am J Surg Pathol. 2007 Feb;31(2):285-90. doi: 10.1097/01.pas.0000213362.10756.d3.
3
TLE1 as a diagnostic immunohistochemical marker for synovial sarcoma emerging from gene expression profiling studies.TLE1作为一种通过基因表达谱研究发现的滑膜肉瘤诊断性免疫组化标志物。
Am J Surg Pathol. 2007 Feb;31(2):240-6. doi: 10.1097/01.pas.0000213330.71745.39.
4
A novel biomarker for the detection of esophageal adenocarcinoma.一种用于检测食管腺癌的新型生物标志物。
J Thorac Cardiovasc Surg. 2007 Jan;133(1):82-7. doi: 10.1016/j.jtcvs.2006.09.011. Epub 2006 Dec 4.
5
Prognostic significance of vascular endothelial growth factor protein levels in T1-2 N0 laryngeal cancer treated with primary radiation therapy.原发性放射治疗的T1-2 N0期喉癌中血管内皮生长因子蛋白水平的预后意义
Cancer. 2007 Feb 1;109(3):566-73. doi: 10.1002/cncr.22432.
6
p27(Kip1) and cyclin E expression and breast cancer survival after treatment with adjuvant chemotherapy.p27（Kip1）和细胞周期蛋白E的表达与辅助化疗治疗后的乳腺癌生存率
J Natl Cancer Inst. 2006 Dec 6;98(23):1723-31. doi: 10.1093/jnci/djj467.
7
Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival.使用新型兔单克隆抗体SP1对乳腺癌雌激素受体进行免疫组织化学检测，在预测生存率方面优于小鼠单克隆抗体1D5。
J Clin Oncol. 2006 Dec 20;24(36):5637-44. doi: 10.1200/JCO.2005.05.4155. Epub 2006 Nov 20.
8
Interlaboratory comparison of immunohistochemical testing for HER2: results of the 2004 and 2005 College of American Pathologists HER2 Immunohistochemistry Tissue Microarray Survey.HER2免疫组化检测的实验室间比对：2004年和2005年美国病理学家学会HER2免疫组化组织微阵列调查结果
Arch Pathol Lab Med. 2006 Oct;130(10):1440-5. doi: 10.5858/2006-130-1440-ICOITF.
9
Cyclin e expression and prognosis in breast cancer patients: a meta-analysis of published studies.乳腺癌患者中细胞周期蛋白E的表达与预后：已发表研究的荟萃分析
Cancer Invest. 2006 Oct;24(6):581-7. doi: 10.1080/07357900600894799.
10
Friend leukaemia integration-1 expression in malignant and benign tumours: a multiple tumour tissue microarray analysis using polyclonal antibody.Friend白血病整合因子-1在恶性和良性肿瘤中的表达：使用多克隆抗体的多肿瘤组织芯片分析
J Clin Pathol. 2007 Jun;60(6):694-700. doi: 10.1136/jcp.2006.039230. Epub 2006 Aug 17.
Zotero 插件